GlassScriptPhysician profile
Haodong Song
NPI 1285704486
$13,930.73
in general payments reported to CMS, 2019-2025
61 companies · $1,911 in 2025
The $1,911 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,334 · 2020: $1,301 · 2021: $2,559 · 2022: $2,642 · 2023: $2,470 · 2024: $1,712 · 2025: $1,911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,978 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,978.15 |
| Education | $115.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,062.97 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Teva Pharmaceuticals USA, INC. | $979.20 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Jazz Pharmaceuticals INC. | $798.11 | 2019-2025 | |
| Biogen, INC. | $779.94 | 2019-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $688.14 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Ucb, INC. | $634.60 | 2019-2024 | Briviact, Nayzilam |
| Novartis Pharmaceuticals Corporation | $505.42 | 2019-2022 | |
| Eisai INC. | $477.58 | 2019-2024 | |
| Pfizer INC. | $463.23 | 2022-2025 | |
| Sk Life Science, INC. | $452.73 | 2020-2025 | Xcopri |
| Allergan, INC. | $444.45 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $396.39 | 2020-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $379.71 | 2022-2025 | Vyepti, Rexulti, Brintellix |
| Upsher-Smith Laboratories LLC | $334.58 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $334.04 | 2022-2024 | Caplyta |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haodong Song listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.